Pacific Biosciences of California Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Pacific Biosciences of California hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-1.8%

Rückkaufsrendite

Gesamte Aktionärsrendite	-1.8%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von PACB in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von PACB gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Pacific Biosciences of California Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von PACB im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (PACB)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Life Sciences)	0.5%
Analystenprognose (PACB) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von PACB im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von PACB im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von PACB, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da PACB keine Ausschüttungen gemeldet hat.

Pacific Biosciences of California Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

New minor risk - Shareholder dilution

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

President recently sold US$173k worth of stock

President notifies of intention to sell stock

Chief Operating Officer recently sold US$63k worth of stock

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Chief Operating Officer notifies of intention to sell stock

Consensus EPS estimates fall by 47%

Price target decreased by 7.8% to US$3.92

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded

Price target decreased by 7.2% to US$5.40

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

New major risk - Share price stability

Price target decreased by 16% to US$8.44

Consensus revenue estimates decrease by 11%, EPS upgraded

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Price target decreased by 11% to US$9.41

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought US$176k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

President recently sold US$481k worth of stock

President notifies of intention to sell stock

Price target decreased by 9.2% to US$11.17

Full year 2023 earnings: EPS misses analyst expectations

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold US$241k worth of stock

Price target decreased by 7.7% to US$11.92

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

Price target decreased by 7.3% to US$12.67

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Price target decreased by 10% to US$13.92

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold US$980k worth of stock

President notifies of intention to sell stock

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Chief Operating Officer recently sold US$287k worth of stock

Chief Operating Officer notifies of intention to sell stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Price target increased by 8.6% to US$14.73

Now 20% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt